Chemotherapy Induced Oral Mucositis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Chemotherapy Induced Oral Mucositis – Drugs In Development, 2024 report and make more profitable business decisions.
Oral mucositis is an inflammation of oral mucosa most commonly occurs after chemotherapy. It is an adverse effect associated with chemotherapy and most found in patients on chemo regimen. Cytotoxic damage to the submucosal cells causes mucositis. It occurs generally after 1 week of chemo and 2 weeks after radiation therapy. It can spread from mouth to anu affecting the whole GI tract and at increased risk of developing infections. Dry mouth, sore throat, mouth ulcers, oral thrush are common symptoms. Infection if spreads to GI tract diarrhea, vomiting, abdominal cramps are seen. Uncomplicated cases requires supportive therapy while in other cases topical anesthetics to relieve pain, normal saline, salt based mouth washes to keep hygienic.
The Chemotherapy Induced Oral Mucositis drugs in development market research report provide comprehensive information on the therapeutics under development for Chemotherapy Induced Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Oral Mucositis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Chemotherapy Induced Oral Mucositis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 11 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Chemotherapy Induced Oral Mucositis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Chemotherapy Induced Oral Mucositis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Chemotherapy Induced Oral Mucositis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Astellas Pharma IncEnzychem Lifesciences Corp
Galera Therapeutics Inc
Genekey Biotech Chengdu Co Ltd
Innovation Pharmaceuticals Inc
Maruho Co Ltd
Spherium Biomed SL
Sunny Pharmtech Inc
Supportive Therapeutics LLC
Tosk Inc
VasoDynamics Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Chemotherapy Induced Oral Mucositis reports